Herein, we explored potential biomarkers related to the outcomes of second‐line osimertinib treatment in patients with EGFR T790M‐mutated advanced NSCLC based on the genomic features obtained by ctDNA sequencing in conjunction with pretreatment clinical characteristics. This evidence concerns the gene EGFR and non-small cell lung carcinoma.